Orhan Efe1, Ashish Verma2, Sushrut S Waikar2. 1. Department of Medicine, Saint Vincent Hospital, Worcester. 2. Division of Renal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Hyperoxaluria can cause kidney disease through multiple mechanisms, including tubular obstruction from calcium oxalate crystals, sterile inflammation, and tubular epithelial cell injury. Hyperoxaluria is also observed in individuals with diabetes mellitus and obesity, which are in turn risk factors for chronic kidney disease (CKD). Whether hyperoxaluria is a potential mediator of increased risk of CKD in diabetes mellitus and obesity is unknown. RECENT FINDINGS: Individuals with diabetes have increased levels of plasma glyoxal (a protein glycation product) and glyoxylate, both of which are precursors for oxalate. Increased gut absorption of oxalate in obesity may be because of obesity-associated inflammation. A recent study in individuals with CKD found that higher 24 h urinary oxalate excretion was independently associated with increased risk of kidney disease progression, especially in individuals with diabetes and obesity. SUMMARY: Both diabetes mellitus and obesity are associated with higher urinary oxalate excretion through distinct mechanisms. Hyperoxaluria could be a mechanism by which kidney disease develops in individuals with diabetes mellitus or obesity and could also contribute to progressive loss of renal function. Future research on pharmacologic or dietary measures to limit oxalate absorption or generation are required to test whether lowering urinary oxalate excretion is beneficial in preventing kidney disease development and progression in diabetes mellitus and obesity.
PURPOSE OF REVIEW: Hyperoxaluria can cause kidney disease through multiple mechanisms, including tubular obstruction from calcium oxalate crystals, sterile inflammation, and tubular epithelial cell injury. Hyperoxaluria is also observed in individuals with diabetes mellitus and obesity, which are in turn risk factors for chronic kidney disease (CKD). Whether hyperoxaluria is a potential mediator of increased risk of CKD in diabetes mellitus and obesity is unknown. RECENT FINDINGS: Individuals with diabetes have increased levels of plasma glyoxal (a protein glycation product) and glyoxylate, both of which are precursors for oxalate. Increased gut absorption of oxalate in obesity may be because of obesity-associated inflammation. A recent study in individuals with CKD found that higher 24 h urinary oxalate excretion was independently associated with increased risk of kidney disease progression, especially in individuals with diabetes and obesity. SUMMARY: Both diabetes mellitus and obesity are associated with higher urinary oxalate excretion through distinct mechanisms. Hyperoxaluria could be a mechanism by which kidney disease develops in individuals with diabetes mellitus or obesity and could also contribute to progressive loss of renal function. Future research on pharmacologic or dietary measures to limit oxalate absorption or generation are required to test whether lowering urinary oxalate excretion is beneficial in preventing kidney disease development and progression in diabetes mellitus and obesity.
Authors: Abigail Liebow; Xingsheng Li; Timothy Racie; Julia Hettinger; Brian R Bettencourt; Nader Najafian; Patrick Haslett; Kevin Fitzgerald; Ross P Holmes; David Erbe; William Querbes; John Knight Journal: J Am Soc Nephrol Date: 2016-07-18 Impact factor: 10.121
Authors: Sushrut S Waikar; Anand Srivastava; Ragnar Palsson; Tariq Shafi; Chi-Yuan Hsu; Kumar Sharma; James P Lash; Jing Chen; Jiang He; John Lieske; Dawei Xie; Xiaoming Zhang; Harold I Feldman; Gary C Curhan Journal: JAMA Intern Med Date: 2019-04-01 Impact factor: 21.873
Authors: Felix Knauf; John R Asplin; Ignacio Granja; Insa M Schmidt; Gilbert W Moeckel; Rachel J David; Richard A Flavell; Peter S Aronson Journal: Kidney Int Date: 2013-06-05 Impact factor: 10.612
Authors: Prince Singh; Jason K Viehman; Ramila A Mehta; Andrea G Cogal; Linda Hasadsri; Devin Oglesbee; Julie B Olson; Barbara M Seide; David J Sas; Peter C Harris; John C Lieske; Dawn S Milliner Journal: Nephrol Dial Transplant Date: 2022-04-25 Impact factor: 7.186
Authors: Peter Fong; Raghav Wusirika; Jose Rueda; Kalani L Raphael; Shehzad Rehman; Megan Stack; Angelo de Mattos; Renu Gupta; Kendall Michels; Firas G Khoury; Vanderlene Kung; Nicole K Andeen Journal: Kidney Int Rep Date: 2022-09-11
Authors: Anja Pfau; Theresa Ermer; Steven G Coca; Maria Clarissa Tio; Bernd Genser; Martin Reichel; Fredric O Finkelstein; Winfried März; Christoph Wanner; Sushrut S Waikar; Kai-Uwe Eckardt; Peter S Aronson; Christiane Drechsler; Felix Knauf Journal: J Am Soc Nephrol Date: 2021-07-19 Impact factor: 14.978